Добавил:
ivanov666
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Хронический кардиоренальный синдром
.pdf
167. Kjaer A. Heart failure and neuroendocrine activation:
diagnostic, prognostic and therapeutic perspective / A. Kajer,
B. Hesse // Clin Physiol. – 2001. – Vol. 21, N. 6. – P. 661–672.
168. Kielstein J.T. Marked increase asymmetrical dimethyarginine in
patients with incipient primary chronic disease / J.T. Kielstein //
J Am Soc Nephrol. – 2002. – Vol. 13, N. 1. – P. 170–176.
169. Kim J. Renal nerves drive interstitial brogenesis in
obstructive nephropathy / J. Kim, B.J. Padanilam // J Am Soc
Nephrol. – 2013. – Vol. 24, N. 2. – P. 229–242.
170. Kim S.H. Indoxyl sulfate–induced epithelial–to–
mesenchymal transition and apoptosis of renal tubular
cells as a novel mechanism of progression of renal disease /
S. H. Kim // Lab Invest. – 2012. – Vol. 92, N. 4. – P. 488–498.
171. Kiyomoto H. Chronic blockade of the (pro)renin receptor
ameliorated the kidney damage in non–clipped kidney
of Goldblatt hypertension / H. Kiyomoto, K. Moriwaki //
Hypertes Res. – 2011. – Vol. 34, N. 3. – P. 289–291.
172. Klein I.H. Sympathetic nerve activity inappropriately
increased in chronic kidney disease / I.H. Klein // J Am Soc
Nephrol. – 2003. – Vol. 14, N. 12. – P. 3239–3244.
173. Klosinska M. Endothelium–dependent and endothelium
independent vasodilatation is more attenuated in ischemic
than non–ischemic heart failure / M. Klosinska // Eur J Heart
Fail. – 2009. – Vol. 11, N. 8. – P. 765–770.
174. Komajda M. Tolerability of carvedilol and ACE–inhibitor in
mild heart failure: results of CARMEN (Carvedilol ACE–
inhibitor remodeling mild HF evaluation) / M. Komajda //
Eur J Heart Fail. – 2004. – Vol. 6, N. 4. – P. 467–475.
175. Kostapanos M.S. Rosuvastatin increases alpha–1
microglobulin urinary excretion in patients with primary
dyslipidaemia / M.S. Kostapanos // J Clin Pharmacol. – 2006. –
Vol. 46, N. 11. – P. 1337–1342.
176. Krebs C. Eect of (pro)renin receptor inhibition on by
a decoy peptide on renal damage in the clipped kidney of
Goldblatt rats / C. Krebs // Kidney Int. – 2008. – Vol. 74,
N. 6. – P. 823–824.
221
177. Krum H. Direct renin inhibition to or as an alternative to
angiotensin converting enzyme inhibition in patients with
chronic systolic heart failure: rationale and design of the
Aliskiren Trial to minimize Outcomes in Patients with Heart
Failure (ATMOSPHERE) study / H. Krum // Eur J Heart Fail. –
2011. – Vol. 13, N. 1. – P. 107–114.
178. Kunz R. Meta–analysis: eect of monotherapy and
combination therapy with inhibitors of renin–angiotensin
system on proteinuria in renal disease / R. Kunz // Ann
Intern Med. – 2008. – Vol. 148, N. 1. – P. 30–48.
179. Lalouel J–M. Angiotensinogen in essential hypertension:
from genetics to nephrology / J–M. Lalouel // J Am Soc
Nephrol. – 2001. – Vol. 12, N. 3. – P. 606–615.
180. Lekawanvijit S. Does indoxyl sulfate, a uremic toxin, have direct
eects on cardiac broblast and myocytes? / S. Lekawanvijit //
Eur Heart J. – 2010. – Vol. 31, N. 14. – P. 1771–1779.
181. Lekawanvijit S. Chronic kidney disease – induced cardiac
brosis is ameliorated by reducing circulating levels of non–
dialyzable toxin indoxyl sulfate / S. Lekawanvijit // Plos One. –
2012. – Vol. 7, N. 7. – P. e4181.
182. Lennemas H. Clinical pharmacokinetics of atorvastatin //
Clin Pharmacokinet. – 2003. – Vol. 42, N. 13. – P. 1141–1160.
183. Levey A.S. A simplied equation to predict glomerular
ltration rate from serum creatinine / A.S. Levey // J Am Soc
Nephrol. – 2000. – Vol. 11, suppl. – P. 155A.
184. Levey A.S. A new equation to estimate glomerular ltration
rate / / A.S. Levey // Ann Intern Med. – 2009. – Vol. 150,
N. 6. – P. 604–612.
185. Levin A. Clinical epidemiology of cardiovascular disease in
chronic kidney disease prior to dialysis // Semin Dial. – 2003. –
Vol. 16, N. 2. – P. 101–105.
186. Levitan D. Plasma catecholamines and autonomic nervous
system function in patients with early renal insuciency
and hypertension / D. Levitan, S.G. Massry, M. Romo //
Nephron. – 1984. – Vol. 36. – N. 1. – P. 24–29.
222
187. Ljungman S. Role of the kidney in congestive heart
failure. Relationship of cardiac index to kidney function
/ S. Ljungman, J.H. Laragh, R.L. Cody // Drugs. – 1990. –
Vol. 39, Suppl. 4. – P. 10–21.
188. Liangos O. Urinary N–acetyl–beta–(D)–glucosaminidase
activity and kidney injury molecule–1 level are associated
with adheres outcomes in acute renal failure / O. Liangos //
J Fm Soc Nephrol. – 2007. – Vol. 18, N. 3. – P. 904–912.
189. Lim A.I. Kidney injury molecule–1: more than just an injury
marker of the epithelial cells / A.I. Lim // J Cell Physiol. –
2013. – Vol. 228, N. 5. – P. 917–924.
190. Liu G. Prorenin induces vascular smooth muscle cell
proliferation and hypertrophy via epidermal growth factor
receptor–mediating extracellular signal–regulating kinase
and Akt activation pathway / G. Liu // J Hypertens. – 2011. –
Vol. 29, N. 4. – P. 696–705.
191. Liu Y. New insights into epithelial–to–mesenchymal
transition in kidney brosis // J Am Soc Nephrol. – 2010. –
Vol. 21, N. 2. – P. 212–222.
192. Lutken S.C. Changes of renal AQP2, ENaC, and NHE3 in
experimentally induced heart failure: response to angiotensin
II AT1 receptor blockade / S.C. Lutken // Am J Physiol Renal.
– 2009. – Vol. 297, N. 6. – P. F1678–F1688.
193. Luvai A. Rosuvastatin: a review of the pharmacology and
clinical eectiveness in cardiovascular disease / A. Luvai,
W. Mbagaya, A.S. Hall // Clin Med Insights Cardiol. – 2012 –
N. 6. – P. 17–33.
194. Ma T. K. Renin–angiotensin–aldosterone system blockade
for cardiovascular disease: current status / T. Ma, K.K. Kam,
B. P. Yan // Br J Pharmacol. – 2010. – Vol. 160, N. 6. –
P. 1273–1292.
195. Maiore A. Angiotensin–converting enzyme inhibitors,
angiotensin receptor blockers and combined therapy in
patients with micro– and macroalbuminuria and other
cardiovascular risk factors: a systematic review of randomized
223
controlled trials / A. Maiore // Nephrol Dial Transplant. –
2011. – Vol. 26, N. 9. – P. 2827–2847.
196. Mancia G. Guidelines for management of Arterial
hypertension. e Task Force for the management of Arterial
Hypertension of the European Society of Hypertension (ESH)
and the EUROPEAN Society of Cardiology (ESC) / G. Mancia
// J Hypertens. – 2007. – Vol. 25, N. 6. – P. 1105–1187.
197. Mann J.F. Renal insuciency as predictor of cardio–vascular
outcomes and impact of ramipril: the HOPE randomization
trial / J.F. Mann // Ann Intern Med. – 2001. – Vol. 134,
N. 2. – P. 629–636.
198. Manotham K. Evidence of tubular hypoxia in the early phase
in the remnant kidney model / K. Manotham // J Am Soc
Nephrol. – 2004. – Vol. 15, N. 5. – P. 1277–1288.
199. Manotham K. Transdierentiation of cultured tubular cells
induced by hypoxia / K. Manotham // Kidney Int. – 2004. –
Vol. 65, N. 3. – P. 871–880.
200. Manotham K. Angiotensin II receptor blocker partially
ameliorated intrarenal hypoxia in chronic kidney disease /
K. Manotham // Intern Med J. – 2012. – Vol. 42, N. 4. –
P. e33–e37.
201. Margi P. Abnormalities of sodium reabsorption in the
proximal nephron in the mild heart failure / P. Margi //
J Nephrol. – 1997. – Vol. 10, N. 1. – P. 50.
202. Margi P. Early impairment of renal hemodynamic reserve
in patients with asymptomatic heart failure is restored by
angiotensin II antagonism / Circulation. – 1998. – Vol. 98,
N. 25. – P. 2849–2854.
203. Martin J.S. Microlaments are involved in renal cell response
to sustained hydrostatic pressure / J.S. Martin, L.S. Brown,
K. M. Haberstrah // J. Urol. – 2005. – Vol. 173, N. 4. –
P. 1410–1417.
204. Martinez D.V. Cardiac damage prevention by eplerenone:
comparison with low sodium diet or potassium loading
224
/ D.V. Martinez // Hypertension. – 2002. – Vol. 39, N. 2. –
P. 614–618.
205. Masson S. Prevalence and prognostic value of elevated urinary
albumin excretion in patients with chronic heart failure: date
from FISSI–Heart Failure trial / S. Masson // Circ Heart Fail. –
2010. – Vol. 3, N. 1. – P. 65–72.
206. Masuyama T. Superiority of long–acting to short–acting loop
diuretics in the management of congestive heart failure /
T. Masuyama // Circ J. – 2012. – Vol. 76, N. 4. – P. 833 – 842.
207. Mathew J. Chronic kidney disease and cardiac remodeling
in patients with mild heart failure: results from the
resynchronization reverses remodeling in systolic le
ventricular dysfunction (REVERSE) study / S. Mathew // Eur
J Heart Fail. – 2012. – Vol. 14, N. 12. – P. 1420–1428.
208. Matsumoto M. Hypoperfusion of peritubular capillaries
induces chronic hypoxia before progression of
tubulointerstitial injury in a progressive model of rat
glomerulonephritis / M. Matsumoto // J Am Soc Nephrol. –
2004. – Vol. 15, N. 6. – P. 1574–1581.
209. Mattock M.B. Microalbuminuria in coronary heart disease in
NIDDM: an incidence study / M.B. Mattock // Diabetes. –
1998. – Vol. 47, N. 11. – P. 1786–1792.
210. Maxwell P.H. Hypoxia–inducible factor as a physiological
regulator // Exp Physiol. – 2005. – Vol. 90, N. 6. – P. 791–797.
211. McAlister F.A. Renal insuciency and heart failure:
prognostic and therapeutic implications from a prospective
cohort study / F.A. McAlister // Circulation. – 2004. –
Vol. 109, N. 8. – P. 1004–1009.
212. McAlister F.A. Renal dysfunction in patients with heart failure
preserved versus reduced ejection fraction: impact of the new
Chronic Kidney Disease Epidemiology Collaboration Group
formula F.A. McAlister // Circ Heart Fail. – 2012. – Vol. 5,
N. 3. – P. 309–314.
213. McClellan W. e prevalence of anemia in patients with
chronic kidney disease / W. McClellan // Curr Med Res Opin. –
2004. – Vol. 20, N. 9. – P. 1501–1510.
225
214. McMurray J.J. Eect of oral direct renin inhibitor aliskiren
in patients with symptomatic heart failure / J.J. McMurray //
Circ Heart Fail. – 2008. – Vol. 1, N. 1. – P. 17–24.
215. McMurray J.J. Aliskiren, ALTITUDE and the implications for
ATMOSPHERE / J.J. McMurray // Eur J Heart Fail. – 2012. –
Vol. 14, N. 4. – P. 341–343.
216. Miyazaki T. Indoxyl sulfate increases the gene expression of
TGF–β
, TIMP–1 and pro(α1) collagen in uremic rat kidney /
1
T. Miyazaki // Kidney Int. – 1997. – Vol. 52, suppl. – P. S15–S22.
217. Menon V. Relationship between homocysteine and mortality
in chronic kidney disease / V. Menon // Circulation. – 2006. –
Vol. 113, N. 12. – P. 1572–1577.
218. Moerti D. Dose dependent eects of omega–3 polyunsaturated
fatty acids on systolic le ventricular function, endothelial
function, and markers of inammation in chronic heart
failure of nonischemic origin / D. Moerti // Am Heart J. –
2011. – Vol. 161, N. 5. – P. e 1–e 9.
219. Moran A. Le ventricular hypertrophy in mild and moderate
reduction of kidney function determined using cardiac
magnetic resonance imaging and cystatin C: the multi–ethnic
study of atherosclerosis (MESA) / A. Moran // Am J Kidney
Dis. – 2008. – Vol. 52, N. 5. – P. 839–848.
220. Moriyama T. Benecial eect of aliskiren combined with
olmesartan in reducing with chronic urinary protein excretion
in patients with chronic kidney disease / T. Moriyama,
Y. Tsuruta, C. Kojima // Int Urol Nephrol. – 2012. – Vol. 44,
N. 3. – P. 841–845.
221. Mullens W. Importance of venous congestion for worsening
of renal function in advanced decompensated heart failure /
W. Mullens // J Am Coll Cardiol. – 2009. – Vol. 53, N. 7. –
P. 589–596.
222. Muteliefu G. Indoxyl sulfate promotes proliferation of human
aortic smooth muscle cells by inducing of oxidative stress //
G. Muteliefu, A. Enomoto, T. Niwa // J Ren Nutr. – 2009a. –
Vol. 19, N. 1. – P. 29–32.
226
223. Muteliefu G. Indoxyl sulfate induced oxidative stress and the
expression of osteoblast–specic proteins in vascular smooth
muscle cells / G. Muteliefu // Nephrol Dial Transplant. –
2009б. – Vol. 24, N. 7. – P. 2551–2558.
224. Nakano T. Association of kidney function with coronary
atherosclerosis and calcication in autopsy samples from
Japanese elders: the Hisayama study / T. Nakano // Am J
Kidney Dis. – 2010. – Vol. 55, N. 1. – P. 21–30.
225. Nakamura S. Microalbuminuria and cardio–vascular events
in elderly hypertensive patients without previous cardio–
vascular implications / S. Nakamura // Hypertens Res. –
2003. – Vol. 26, N. 8. – P. 603–608.
226. Namba S. A serum indoxyl sulfate is a useful predictor for
progression of chronic kidney disease / S. Namba // Rinsho
Byori. – 2010. – Vol. 58, N. 5. – P. 448–453.
227. Nanayakkara P.W. Plasma asymmetric dimetylarginine
(ADMA) concentration is independently associated with
carotid intima–media sickness and plasma soluble vascular
cell adhesion molecula–1 (sVCAM) concentration in patients
with mild to moderate renal failure / P.W. Nanayakkara //
Kidney Int. – 2005. – Vol. 68, N. 5. – P. 2230–2236.
228. Nangaku M. Chronic hypoxia and tubular interstitial injury:
a nal common pathway to end–stage renal failure / / J Am
Soc Nephrol . – 2006. – Vol. 17, N. 1. – P. 17–25.
229. Nangaku M. Angiotensin induced hypoxia in the kidney:
functional and structural changes of the renal circulation /
M. Nangaku, R. Inagi, T. Miyata // Adv Exp Med Biol. – 2007. –
N. 618. – P. 85–99.
230. Nangaku M. Hypoxia and hypoxia–inducible factor in renal
disease / M. Nangaku, R. Inagi, T. Miyata // Nephron Exp
Nephrol. – 2008. – Vol. 110, N. 1. – P. e1–е7.
231. National Kidney Foundation. Kidney Disease Outcome Quality
Initiative (K/DOQI) clinical practice guidelines for chronic
kidney disease: evaluation, classication and stratication //
Am J Kidney Dis. – 2002. – Vol. 139, suppl. – P. S1–S226.
227
232. Narodi E. Le ventricular hypertrophy and geometry in
hypertensive patients with chronic renal disease / E. Narodi
// J Hypertens. – 2009. – Vol. 27, N. 3. – P. 633–641.
233. Navaneethan S.D. Aldosterone antagonist prevents the
progression of chronic kidney disease: a systematic review
and meta–analysis / S.D. Navaneethan, S.U. Nigwekar,
A.R. Seghal // Clin J Am Soc Nephrol. – 2009. – Vol. 4, N. 3. –
P. S545–S551.
234. Nemerovski C. Treatment of hypervolemic or hypovolemic
hyponatriemia associated with heart failure, cirrosis or
the syndrome of inappropriate antidiuretic hormone with
tolvaptan: a clinical review / C. Nemerovski, D.J. Hutchinson
// Clin er. – 2010. – Vol. 32, N. 6. – P. 1015–1032.
235. Neusser M.A. Human nephrosclerosis triggers: hypoxia–
related glomerulopathy / M.A. Neusser // Am J Pathol. –
2010. – Vol. 176, N. 2. – P. 594–607.
236. Newsome B.B. Long–term risk of mortality and stage of
renal disease among the elderly aer small increase of serum
creatinine level during hospitalization for acute myocardial
infarction / B.B. Newsome // Arch Intern Med. – 2008. –
Vol. 168, N. 6. – P. 609–615.
237. Niizuma S. Decreased coronary ow reserve in hemodyalisis
patients / S. Niizuma // Nephrol Dial Transplant. – 2008. –
Vol. 23, N. 7. – P. 2324–2328.
238. Nishikimi T. Eect of alpha–1 adrenergic blockade on
intrarenal hemodynamics in heart failure rats / T. Nishikimi,
K. Ochino, E.D. Frohlich // Am J Physiol. – 1992. – Vol. 262,
N. 2. – P. R198–R203.
239. Numabe A. Intrarenal hemodynamics in low– and high–output
cardiac failure rats / A. Numabe, K. Komatsu, E.D. Frohlich //
Am J Med Sci. – 1994. – Vol. 308, N. 6. – P. 331–337.
240. Oda Y. Renal insuciency coexisting with heart failure is
related to elevated sympathetic nerve activity / Y. Oda //
Auton Neurosci. – 2010. – Vol. 155, N. 1–2. – P. 104–108.
241. Ohuchi H. Impact of central venous pressure on cardiorenal
228
interactions in adult patients with congenital heart disease
aer biventricular repair / H. Ohuchi // Congenit. Heart
Dis. – 2013. – Vol. 8, N. 2. – P. 103–110.
242. Okuda Y. Long–term eects of eicosapentaenoic acid on
diabetic peripheral neuropathy and serum lipids in patients
with type II diabetes mellitus / Y. Okuda // J Diabetes
Complications. – 1996. – Vol. 10, N. 5. – P. 280–287.
243. Onuigbo M.A. Can ACE inhibitors and angiotensin receptor
blockers be determinant in CKD patients // Nephron Clin
Prac. – 2011. – Vol. 118, N. 4. – P. 407–419.
244. Ooi H. Arterial stiness and vascular load in heart failure /
H. Ooi, W. Chung, A. Biolo // Congest Heart Fail. – 2008. –
Vol. 14, N. 1. – P. 31–36.
245. Orea–Tejeda A. Microalbuminuria in systolic and diastolic
chronic heart failure patients / A. Orea–Tejeda // Cardiol J. –
2008. – Vol. 15, N. 2. – P. 143–149.
246. Orphanides C. Hypoxia stimulates proximal tubular cell
matrix production via TGF–β
–independent mechanism /
1
C. Orphanides, L.G. Fine, J.T. Norman // Kidney Int. – 1997.
– Vol. 52, N. 3. – P. 637–647.
247. Osicka T.M. Protein degradation during renal passage in
normal kidney is inhibited in experimental albuminuria
/ T.M. Osicka, W.D. Comper // Clin Sci. – 1997. – Vol. 93,
N. 1. – P. 65–72.
248. Ovedeji A.T. e signicance of mild renal dysfunction in
chronic heart failure / A.T. Ovedeji // West Afr J Med. –
2011. – Vol. 30, N. 6. – P. 442–446.
249. Palazzuoli A. Anemia correction by erythropoietin reduced
BNP levels, hospitalization rate, and NYHA class in patients
with cardio–renal anemia syndrome / A. Palazzuoli // Clin
Exp Med. – 2011. – Vol. 11, N. 1. – P. 43–48.
250. Palmer S.C. Benets and harms of statin therapy for persons
with chronic kidney disease: s systematic review and meta–
analysis / S. C. Palmer // Ann Intern Med. – 2012. – Vol. 157,
N. 4. – P. 263–275.
229
251. Paoletti E. Is le ventricular hypertrophy a powerful
predictor of progression to dialysis in chronic kidney disease
/ E. Paoletti // Nephron Dial Transplant. – 2011. – Vol. 26,
N. 2. – P. 670–677.
252. Parving H.H. Aliskiren combined with losartan in type 2
diabetes and nephropathy / H.H. Parving // N Engl J Med. –
2008. – Vol. 358, N. 23. – P. 2433–2446.
253. Parving H.H. Aliskiren Trial in type 2 diabetes Using
Cardiorenal Endpoints (ALTITUDE): rationale and study
design / H.H. Parving // Nephrol Dial Transplant. – 2009. –
Vol. 24, N. 5. – P. 1636–1671.
254. Parving H.H. Baseline characteristics in the Aliskiren
Trial in the type 2 Diabetes Using Cardiorenal Endpoints
(ALTITUDE) / H.H. Parving // J Renin Angiotensin
Aldosterone Syst. – 2012. – Vol. 13, N. 3. – P. 387–393.
255. Patel U.D. Quality of care and outcomes among patients
with heart failure and chronic kidney disease: a get with the
guidelines–heart failure program study / U.D. Patel // Am
Heart J. – 2008. – Vol. 156, N. 4. – P. 674–681.
256. Persson F. Impact of baseline renal function on the ecacy
and safety aliskiren added to losartan inpatients with type 2
diabetes and nephropathy / F. Persson // Diabetes Care. –
2010. – Vol. 33, N. 11. – P. 2304–2309.
257. Persson F. Aliskiren in combination with losartan reduces
albuminuria independent of baseline blood pressure in
patients with type 2 diabetes and nephropathy / F. Persson //
Clin J Am Soc Nephrol. – 2011. – Vol. 6, N. 5. – P. 1025–1031.
258. Persson F. Impact of aliskiren treatment on urinary
aldosterone levels in patients with type 2 diabetes and
nephropathy / F. Persson // J Renin Angiotensin Aldosterone
Syst. – 2012. – Vol. 13, N. 1. – P. 118–121.
259. Pitt B. e eect of spironolactone on morbidity and mortality
in patients with severe heart failure. Randomized Aldactone
Evaluation Study Investigators / B. Pitt // N Engl J Med. –
1999. – Vol. 341, N. 10. – P. 709–717.
230
Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]